Nektar Therapeutics announces promising results for Rezpegaldesleukin in treating severe alopecia areata, offering hope for patients.

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock surged 13% Thursday morning following disappointing clinical trial results from Sanofi’s (NASDAQ:SNY) amlitelimab treatment for atopic dermatitis. The positive market reaction for Nektar appears linked to competitive positioning for its own atopic dermatitis candidate. Sanofi’s amlitelimab data, while meeting primary and secondary endpoints in its Phase 3 COAST-1 trial, fell below efficacy expectations according to market observers. This development potentially strengthens the market position of Nektar’s lead drug candidate rezpegaldesleukin (REZPEG), a regulatory T cell stimulator currently in Phase 2b clinical trials for atopic dermatitis and alopecia areata. In June, Nektar announced that its REZOLVE-AD Phase 2b study of rezpegaldesleukin met both primary and key secondary endpoints in patients with moderate-to-severe atopic dermatitis. Nektar Therapeutics focuses on developing treatments that address underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. The company’s REZPEG (NKTR-358) is positioned as a novel, first-in-class regulatory T cell stimulator. The market movement suggests investors view Sanofi’s underwhelming results as potentially beneficial for Nektar’s competitive positioning in the atopic dermatitis treatment landscape. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. With NKTR making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed NKTR alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including NKTR, could offer substantial returns as the market corrects. In 2025 alone, our AI identified several undervalued stocks that later surged by 50% or more. Is NKTR poised for similar growth? Don't miss the opportunity to find out.

Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.

Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results  Investopedia

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock surged 140% after the company announced its experimental drug rezpegaldesleukin met primary and key secondary endpoints in a Phase 2b study for moderate-to-severe atopic dermatitis. The clinical-stage biotech reported that all three dosing arms of rezpegaldesleukin achieved statistical significance on the primary endpoint measuring mean percent change in EASI score from baseline at week 16 compared to placebo. The drug also hit multiple secondary endpoints including EASI-75, EASI-50, and improvements in body surface area affected by the skin condition. The highest dose (24 µg/kg every two weeks) showed a 61% mean improvement in EASI score from baseline, while 42% of patients in this group achieved EASI-75, indicating at least a 75% reduction in disease severity. The drug demonstrated rapid onset of action with improvements in both skin clearance and itch relief. "These data from REZOLVE-AD show a fast onset of both EASI response and itch relief within the first few doses of rezpegaldesleukin treatment, which are important metrics for physicians as they assess treatment options in atopic dermatitis," said Prof. Jonathan Silverberg from George Washington University. Nektar reported that the safety profile remained consistent with previous studies, with injection site reactions being the most common side effect, occurring in 69.7% of treated patients. Unlike some competing treatments, the drug showed no increased risk of conjunctivitis, oral ulcers, or infections. The company plans to continue the long-term maintenance portion of the study, with data expected in the first quarter of 2026. Nektar also anticipates releasing Phase 2b data for the same drug in alopecia areata in the fourth quarter of 2025. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Nektar Therapeutics Presented Phase 2 Results for NKTR-255 at ASH 2024 / ASH24, Cameron J. Turtle, cancer, Catherine S. Diefenbach, Christie Fanton, Cristina